Laser Treatment Reverses Skin Aging at the DNA Level in New Human Study
A non-ablative fractional laser shifted DNA methylation patterns away from aging at 84% of responsive sites, with effects lasting 6 months.
Summary
A new human study published in Scientific Reports found that a non-ablative fractional laser treatment reversed molecular markers of skin aging. Researchers used DNA methylation analysis across 3.8 million genomic sites and found that 84% of age-related sites that responded to treatment shifted in the opposite direction of normal aging. The effects emerged about a month after three laser sessions and remained stable six months later. Visible improvements included a 38% reduction in brown spots. The study also found changes in genes linked to skin cancer biology, suggesting the treatment may do more than improve appearance — it may support skin health at a biological level.
Detailed Summary
Cosmetic laser treatments have long been judged by what the mirror shows. A new study suggests the story goes much deeper, into the biology of how skin ages at the molecular level. Published in Nature's Scientific Reports, the research offers the first in vivo evidence that a non-ablative fractional laser can remodel the skin's epigenetic profile — the chemical tags on DNA that regulate gene activity without altering the genetic code itself.
The study enrolled 22 adults who each received three treatments with Candela's Nordlys 1940 nm non-ablative fractional laser. Using a split-face design, one cheek was treated and the other left untouched, making each participant their own control. Researchers analyzed DNA methylation patterns across more than 3.8 million genomic sites and found that 84% of age-related responsive sites shifted in the direction opposite to normal skin aging — a meaningful reversal signal.
The timing of these changes was notable. Effects did not appear immediately after treatment but emerged roughly one month later, continued strengthening over subsequent months, and remained stable at the six-month follow-up. This suggests the skin continues remodeling itself long after the laser sessions end. Visible outcomes matched the molecular data: a median 38% reduction in brown spots was recorded, alongside improvements in texture and pigmentation.
Genes influenced by the treatment were linked to collagen production, skin barrier integrity, and normal cellular renewal. Researchers also identified changes in DNA methylation at sites associated with basal cell and squamous cell skin cancer biology, aligning with prior clinical data suggesting non-ablative laser treatments may reduce keratinocyte-carcinoma risk.
Caveats are important here. The study was small, industry-affiliated, and not designed to measure cancer prevention outcomes. Longer-term and larger independent trials are needed before clinical recommendations can be made. Still, the findings meaningfully shift how aesthetic medicine may be understood in the context of biological aging and longevity science.
Key Findings
- Non-ablative fractional laser reversed DNA methylation aging markers at 84% of responsive genomic sites in human skin.
- Molecular anti-aging effects emerged one month post-treatment, strengthened over time, and held stable at 6 months.
- Treated skin showed a median 38% reduction in brown spots alongside texture and pigmentation improvements.
- Laser-influenced genes include those governing collagen production, skin barrier function, and skin cell renewal.
- DNA methylation changes linked to skin cancer biology suggest a potential chemopreventive mechanism worth further study.
Methodology
This is a news report summarizing a peer-reviewed human study published in Nature's Scientific Reports. The trial used a well-controlled split-face design with objective epigenomic analysis across 3.8 million genomic sites, though it was small (n=22) and funded by the device manufacturer Candela, introducing potential conflict-of-interest considerations.
Study Limitations
The study involved only 22 participants and was led by a senior employee of Candela, the device manufacturer, raising conflict-of-interest concerns. The trial was not designed to measure cancer prevention, so no clinical claims on that front are justified. Independent replication with larger cohorts and longer follow-up is needed before broad conclusions can be drawn.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: